Waddell & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.91M Sell
33,126
-6,577
-17% -$378K 0.09% 73
2026
Q1
$2.41M Buy
39,703
+15,916
+67% +$928K 0.14% 45
2025
Q4
$1.28M Buy
23,787
+16,780
+239% +$807K 0.09% 67
2025
Q3
$316K Buy
7,007
+459
+7% +$21.4K 0.03% 204
2025
Q2
$303K Buy
6,548
+2,456
+60% +$121K 0.03% 165
2025
Q1
$250K Buy
+4,092
New +$239K 0.03% 142
2024
Q1
Sell
-7,055
Closed -$373K 145
2023
Q4
$373K Sell
7,055
-11,625
-62% -$610K 0.05% 93
2023
Q3
$1.08M Buy
18,680
+126
+0.7% +$7.72K 0.16% 52
2023
Q2
$1.19M Sell
18,554
-16
-0.1% -$1.07K 0.17% 47
2023
Q1
$1.29M Buy
18,570
+76
+0.4% +$5.36K 0.2% 43
2022
Q4
$1.33M Buy
18,494
+93
+0.5% +$7.01K 0.22% 38
2022
Q3
$1.31M Buy
18,401
+86
+0.5% +$6.24K 0.25% 35
2022
Q2
$1.41M Buy
18,315
+124
+0.7% +$9.44K 0.29% 29
2022
Q1
$1.33M Buy
18,191
+3,293
+22% +$221K 0.21% 35
2021
Q4
$929K Buy
14,898
+75
+0.5% +$4.4K 0.15% 44
2021
Q3
$877K Buy
14,823
+78
+0.5% +$5.14K 0.15% 42
2021
Q2
$985 Buy
+14,745
New +$961K 0.15% 35

Other funds holding BMY

Waddell & Associates's BMY Position: Q2 2026 in Review

Waddell & Associates reduced its Bristol-Myers Squibb (BMY) stake by 17% in Q2 2026, selling an estimated $378K and leaving 33,126 shares worth $1.91M. The position accounts for 0.09% of the portfolio, ranked #73.

Waddell & Associates first reported a position in BMY in Q2 2021 and has held it in 17 quarters since. The position peaked at $2.41M in Q1 2026. 878 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Waddell & Associates held 33,126 shares of Bristol-Myers Squibb worth $1.91M as of Q2 2026.
  • Waddell & Associates sold 6,577 Bristol-Myers Squibb shares in Q2 2026, an estimated $378K.
  • Bristol-Myers Squibb made up 0.09% of Waddell & Associates's portfolio in Q2 2026, its #73 holding.
  • Waddell & Associates first reported a position in Bristol-Myers Squibb in Q2 2021 and has held it in 17 quarters since.
  • Waddell & Associates's Bristol-Myers Squibb position peaked at $2.41M in Q1 2026.
  • 878 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Waddell & Associates's 13F filing for Q2 2026, filed 15 Jul 2026.